OVID-19 vaccine proves to be at least 70% effective, the company plans to seek emergency authorization for its use in high-risk groups, the company's chief executive told Reuters.Moderna's vaccine candidate - mRNA-1273 - is nearing the finish line in its push to enroll 30,000 individuals in a late-stage trial of a novel coronavirus vaccine.
But the company may be able to declare victory early if it is able to show that people who got the vaccine fared much better in its trial that people who didn't.Vaccines must demonstrate they are at least 50% more effective than a placebo to be considered for approval.